Results of IgA Nephropathy Therapy with Telitacicept Published in NEJM
The New England Journal of Medicine has published interim results from the Phase 3 trial of telitacicept in IgA nephropathy. Therapy led to a 58.9% reduction in proteinuria compared to 8.8% in the placebo group, with fewer serious adverse events observed.
Telitacicept for IgA Nephropathy: Why the NEJM Publication Marks the Home Stretch in a Decade-Long Race
The Gist: What's Really Happening
On May 13, 2026, The New England Journal of Medicine published results from a prespecified interim analysis of the Phase 3 TELIGAN trial—telitacicept versus placebo in patients with high-risk progressive IgA nephropathy. Formally, this is a presentation of clinical data: a 58.9% reduction in proteinuria versus 8.8% in the placebo group, a relative difference of -55% (p<0.001), and a slowing of eGFR decline (a 1% decrease versus 7.7%). But in reality, this publication marks a tectonic shift in the IgA nephropathy market—a disease that just five years ago was treated almost exclusively with steroids and RAAS inhibitors, and today has become a battlefield for a dozen molecules with a commercial potential of $83 billion.
What actually happened: China's RemeGen stepped onto the global stage with a dual BAFF/APRIL inhibitor that demonstrated efficacy comparable to race leaders—Vertex's povetacicept and Vera Therapeutics' atacicept—in a randomized, double-blind trial with hard endpoints. Publication in NEJM is a seal of quality, opening the door to FDA registration.
Timeline and Context
IgA nephropathy is the most common primary glomerular disease worldwide. There are approximately 300,000 patients in the US and Europe, and over 750,000 in China. About 30–40% of patients reach end-stage renal disease within 20 years, making every new disease-modifying agent a potential billion-dollar asset.
Telitacicept's path to NEJM began long before 2026. The drug is a TACI-Fc fusion protein created using recombinant DNA technology: a fragment of the TACI gene (a receptor that binds both BAFF and APRIL) fused to the Fc portion of human IgG. It is not a monoclonal antibody but a fundamentally different construct capable of neutralizing both key factors for B-cell survival and maturation. Initially, telitacicept was developed for systemic lupus erythematosus and lupus nephritis—in China, it is approved for these indications. Its success in IgA nephropathy was a kind of "side effect" of rational design: BAFF and APRIL are central mediators in the pathogenesis of both conditions.
In 2023, RemeGen launched TELIGAN—Phase 3, 318 patients, 39 weeks of therapy. Key point: the company used a surrogate endpoint (proteinuria reduction) that the FDA had already accepted for accelerated approval of competitors—Otsuka's sibeprenlimab in November 2025 and, expectedly, Vertex's povetacicept. In other words, RemeGen is playing by the same rules as Western companies.
Who Wins and Who Loses
Winners:
- RemeGen: Publication in NEJM immediately boosts the company's credibility with the FDA and EMA. For a Chinese biotech company, this is a ticket to the big leagues. The potential IgA nephropathy market—$83 billion in the long term—is worth investing in overseas registration studies.
- Patients: Each new drug in the BAFF/APRIL class expands choices and pressures prices. Telitacicept is the fourth player after sibeprenlimab (approved), povetacicept (BLA submitted), and atacicept (PDUFA July 7, 2026). Competition in this segment promises a 20–30% reduction in therapy costs over the next three years.
- Nephrologists: Gain another tool with a dual mechanism, potentially superior in depth of effect to monoclonal antibodies targeting a single ligand.
Losers:
- Manufacturers of monoclonal antibodies targeting individual ligands. Telitacicept is a dual inhibitor, giving it a theoretical advantage, although no head-to-head studies exist. Otsuka's sibeprenlimab, approved in November 2025, targets only APRIL; Vera's atacicept is also dual, but its PDUFA is still ahead.
- Companies whose drugs act at later stages of pathogenesis—SGLT2 inhibitors, endothelin receptor antagonists, complement blockers. They reduce proteinuria through hemodynamic effects but do not modify the disease at the level of pathogenic Gd-IgA1 production. With the advent of effective upstream therapies, their role may shrink to adjuvant.
- GSK with belimumab: Belimumab is a BLyS-only inhibitor approved for lupus nephritis. The success of dual BAFF/APRIL inhibitors in IgA nephropathy calls into question the long-term competitiveness of BLyS monotherapy even in its "home" indication.
What the Media Miss
Most coverage focuses on the figure "58.9% reduction in proteinuria." But that's a superficial reading.
Non-obvious insight: Telitacicept is not just another drug but a technology platform that could reshape the autoimmune therapy landscape.
The market views TELIGAN as a success story for RemeGen in IgA nephropathy. But in reality, it validates the TACI-Fc platform itself. Telitacicept is already approved in China for systemic lupus erythematosus and is being studied in lupus nephritis, rheumatoid arthritis, multiple sclerosis, and neuromyelitis optica. Each new NEJM article for a new indication is not just a $5–10 billion market expansion but proof that dual BAFF/APRIL inhibition works across a class of B-cell-mediated autoimmune diseases.
This positions RemeGen similarly to Regeneron with its VEGF trap in the early 2010s: a platform that can churn out indications one after another. The difference is that competition in the BAFF/APRIL segment is already high. But TACI-Fc is a fundamentally different molecule from a monoclonal antibody: it is cheaper to produce, which could be a decisive factor in price wars in Europe and emerging markets.
Forecast: Next 30 Days and 90 Days
30 days (by mid-June 2026):
Expect a wave of commentary from leading nephrologists worldwide in response to the NEJM publication. Watch for editorials in Nature Reviews Nephrology and JASN—they will set the tone for perception of telitacicept. RemeGen will likely announce timelines for BLA submissions to the FDA and EMA. Given that sibeprenlimab has already received accelerated approval and atacicept's PDUFA is set for July 7, 2026, RemeGen needs to hurry: the window of opportunity is narrowing. Meanwhile, investors will reassess Vertex's povetacicept prospects—if telitacicept hits the market simultaneously or earlier, Vertex's projected market share could shrink by 10–15 percentage points.
90 days (by mid-August 2026):
Key catalyst: the decision on Vera Therapeutics' atacicept (PDUFA July 7). If atacicept is approved, the market will solidify as a segment of dual BAFF/APRIL inhibitors with three players (povetacicept, atacicept, telitacicept) plus sibeprenlimab with a mono-APRIL mechanism. RemeGen will likely use TELIGAN data to file under Project Orbis, allowing synchronized registration in the US, Canada, Australia, and possibly select EU countries. Also expected: first real-world evidence data on telitacicept from Chinese clinical practice (the drug has been used for lupus since 2021), providing additional safety arguments.
Long-term—2027 and beyond—the IgA nephropathy market faces a wave of consolidation. Of the dozen molecules in development, only three or four will achieve commercial success. And telitacicept has just proven it is among them.
— Editorial Team
